GlassScriptPhysician profile
Alyson W Smith
NPI 1639107980
$5,972.92
in general payments reported to CMS, 2019-2025
20 companies · $1,182 in 2025
The $1,182 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $362 · 2021: $970 · 2022: $1,238 · 2023: $798 · 2024: $836 · 2025: $1,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,816.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,410.12 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Novartis Pharmaceuticals Corporation | $1,037.85 | 2019-2025 | |
| Glaxosmithkline, LLC. | $881.86 | 2019-2025 | Nucala, Bexsero, Rotarix |
| Regeneron Healthcare Solutions, INC. | $760.84 | 2021-2025 | Dupixent |
| Genentech USA, INC. | $750.85 | 2019-2025 | Xolair |
| Genzyme Corporation | $267.33 | 2021-2025 | |
| Pfizer INC. | $243.20 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.78 | 2021-2022 | |
| Novo Nordisk INC | $68.15 | 2025 | Rybelsus, Ozempic |
| Biocryst US Sales Co., LLC | $64.43 | 2023-2025 | Orladeyo |
| Sobi, INC | $63.88 | 2019-2020 | |
| Amgen INC. | $54.15 | 2024 | Tezspire |
| Sanofi Pasteur INC. | $49.35 | 2025 | |
| Alk-Abello, INC | $49.30 | 2025 | Neffy, Grastek, Odactra |
| Phadia US INC. | $48.57 | 2020-2024 | Immunocap |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $43.73 | 2025 | Neffy |
| Csl Behring | $34.03 | 2023-2024 | Haegarda |
| Kaleo, INC. | $23.73 | 2022 | |
| Seqirus USA INC | $23.07 | 2023 | Flucelvax Quadrivalent |
| Merck Sharp & Dohme LLC | $21.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyson Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.